Literature DB >> 12913407

High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease.

Hiroshi Mohri1.   

Abstract

Menorrhagia is one of the most important and frequent complications in women with congenital von Willebrand disease (vWD). Three cases of menorrhagia with vWD (type 1; 1 case, type 2A; 2 cases) were successfully treated with tranexamic acid at dose of 3 grams daily in four divided doses for the first 5 days of the menstrual cycle. All patients had severe menorrhagia lasted for more than 10 days with iron deficiency anemia of hemoglobin levels of 6.5-8.4 g/dl. Common dosage of tranexamic acid of 1 gram daily in 4 divided doses on days 1-5 of their menstrual cycles did not correct their menorrhagia. The treatment was then changed to the daily dose of 3 grams in 4 divided doses on days 1-5 of their menstrual cycles. Thereafter, their menorrhagia became well-controlled with improvement of their anemia up to hemoglobin of 11.5-12.4 g/dl. High dose of tranexamic acid has been administered safely in all patients for 3-5 years without significant complications. Oral high-dose administration of tranexamic acid is very convenient and useful for treatment of menorrhagia in the patients with vWD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12913407     DOI: 10.1023/a:1025013213192

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  12 in total

Review 1.  von Willebrand factor.

Authors:  Z M Ruggeri
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia.

Authors:  B Andersch; I Milsom; G Rybo
Journal:  Acta Obstet Gynecol Scand       Date:  1988       Impact factor: 3.636

3.  Studies on the mechanism of the antifibrinolytic action of tranexamic acid.

Authors:  M Hoylaerts; H R Lijnen; D Collen
Journal:  Biochim Biophys Acta       Date:  1981-02-18

4.  Menstrual blood loss--a population study. Variation at different ages and attempts to define normality.

Authors:  L Hallberg; A M Högdahl; L Nilsson; G Rybo
Journal:  Acta Obstet Gynecol Scand       Date:  1966       Impact factor: 3.636

5.  Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids.

Authors:  S Thorsen
Journal:  Biochim Biophys Acta       Date:  1975-05-30

Review 6.  Women and inherited bleeding disorders: menstrual issues.

Authors:  C A Lee
Journal:  Semin Hematol       Date:  1999-07       Impact factor: 3.851

7.  Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid.

Authors:  Y L Ong; D R Hull; E E Mayne
Journal:  Haemophilia       Date:  1998-01       Impact factor: 4.287

Review 8.  Treatment of von Willebrand disease.

Authors:  P M Mannucci
Journal:  Haemophilia       Date:  1998-07       Impact factor: 4.287

Review 9.  Diagnosis of von Willebrand disease.

Authors:  A B Federici
Journal:  Haemophilia       Date:  1998-07       Impact factor: 4.287

10.  The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding.

Authors:  N C Gleeson; F Buggy; B L Sheppard; J Bonnar
Journal:  Acta Obstet Gynecol Scand       Date:  1994-03       Impact factor: 3.636

View more
  4 in total

1.  Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.

Authors:  Leifeng Cheng; Daniel Pettersen; Bengt Ohlsson; Peter Schell; Michael Karle; Emma Evertsson; Sara Pahlén; Maria Jonforsen; Alleyn T Plowright; Jonas Boström; Tomas Fex; Anders Thelin; Constanze Hilgendorf; Yafeng Xue; Göran Wahlund; Walter Lindberg; Lars-Olof Larsson; David Gustafsson
Journal:  ACS Med Chem Lett       Date:  2014-02-18       Impact factor: 4.345

Review 2.  A benefit-risk review of systemic haemostatic agents: part 2: in excessive or heavy menstrual bleeding.

Authors:  Ian S Fraser; Robert J Porte; Peter A Kouides; Andrea S Lukes
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 3.  Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis.

Authors:  Ingrid Pabinger; Dietmar Fries; Herbert Schöchl; Werner Streif; Wolfgang Toller
Journal:  Wien Klin Wochenschr       Date:  2017-04-21       Impact factor: 1.704

4.  Expert consensus on the diagnosis and treatment of thrombocytopenia in adult critical care patients in China.

Authors:  Jing-Chun Song; Shu-Yuan Liu; Feng Zhu; Ai-Qing Wen; Lin-Hao Ma; Wei-Qin Li; Jun Wu
Journal:  Mil Med Res       Date:  2020-04-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.